ChromaDex Commences a Clinical Trial on pTeroPure Pterostilbene

The next generation, novel ingredient, is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi.

Sep 8 2010 --- Pterostilbene shows promise as a more potent, next generation resveratrol for improving cardiovascular health, glucose levels, anti-ageing and cognitive function

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, has initiated a clinical study at The University of Mississippi for pTeroPure pterostilbene. The next generation, novel ingredient, is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi.
 
Pterostilbene is chemically related to resveratrol, a compound that can be found in grapes, blueberries, and other small fruits, as well as the bark of some trees. In laboratory tests, pterostilbene has shown promise for improving cardiovascular health, glucose levels, anti-ageing and cognitive function; and, for possessing cancer-fighting properties.  Various scientific publications have shown that pterostilbene has significantly higher activity than resveratrol.
 
The clinical trial is being conducted at the UM Medical Center in Jackson, where investigators hope to evaluate the compound in patients with lipid (cholesterol) disorders. Patients enrolled in the study will receive high and low doses of pterostilbene -with and without grape extract, or a placebo, said Daniel Riche, assistant professor of pharmacy practice and medicine, and the study's principal investigator.
 
"We are excited to be collaborating with ChromaDex on the first clinical investigation for pterostilbene," Dr. Riche said. "Pterostilbene has significant promise, and we hope it will offer a useful non-prescription option for metabolic disorders. In addition to cholesterol and blood pressure, we will be evaluating urine tests and monitoring for inflammatory markers," said Riche. "Reductions in these markers may correlate with improvements in oxidative stress."
 
Assisting Riche with the study are Justin J. Sherman, associate professor of pharmacy practice, and Dr. C. Andrew Brown, professor of medicine at the UM Medical Center in Jackson.
 
"The commencement of our pTeroPure pterostilbene clinical study with the University of Mississippi marks another significant milestone for ChromaDex," said Frank Jaksch, CEO and co-founder of ChromaDex.  "Most people may not yet know of pterostilbene, but we believe this naturally occurring compound's improved activity and potency may soon make it as well known as its highly-successful, well known relative, resveratrol."